Biotie Provides Update on Tozadenant


(February 26, 2015) - Biotie announces further detail on its clinical development plan for tozadenant, an adenosine A2a antagonist in development for treatment of Parkinson's disease (PD). The primary endpoint of Biotie’s Phase 3 study of PD patients experiencing levodopa related end-of-dose 'wearing-off' (motor fluctuations) will be time spent in the "off" state in patients taking tozadenant versus a placebo. Based on current estimates, top-line data is expected to be available by the end of 2018. Read more…

Click for a printer friendly version

Back to top